Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 3

1(20.0%)

N/A

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 2(2)

Phase 3(1)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05766839Phase 2Recruiting

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

Role: lead

NCT06256991Phase 4Recruiting

Potassium Correction for RAAS Optimization in Chronic Kidney Disease

Role: collaborator

NCT05034250Unknown

Iron Status in Female Infertility and Recurrent Miscarriage

Role: collaborator

NCT05861492Not ApplicableTerminated

FDDA Utilization Study (FDDAU)

Role: lead

NCT03888066Phase 3Completed

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Role: lead

NCT03087058Phase 2Terminated

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

Role: lead

All 6 trials loaded